Physician profile

Patrick B Higdon

Hospitalist · Corpus Christi, TX

NPI 1003812785

$259.77

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$24.28

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $124.94 2021
Kowa Pharmaceuticals America, INC. $26.99 2021-2022
Novartis Pharmaceuticals Corporation $24.90 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $24.28 2024 Lifevest
Ucb, INC. $21.50 2019
Almatica Pharma LLC $20.59 2022
Astrazeneca Pharmaceuticals Lp $16.57 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Patrick B Higdon

$259.77

in general payments reported 2019-2025

Years
2019-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/990033/patrick-b-higdon

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.